By Fineline Cube 
Zhaoke Ophthalmology Limited (HKG: 6622), a leading China‑based ocular therapeutics company, announced today that it has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the Indonesian market. The deal grants PT Ferron exclusive rights to import, promote, distribute, market, and sell NVK002, Zhaoke’s flagship topical atropine‑sulphate ophthalmic solution, in Indonesia.
Deal Highlights
| Element | Detail |
|---|---|
| Partner | PT Ferron Par Pharmaceuticals – Indonesia’s leading pharma company |
| Product | NVK002 – investigational atropine‑sulphate topical solution |
| Territory | Indonesia (exclusive) |
| Payments | Up‑front payment + milestone‑based payments tied to sales & regulatory achievements |
| Target Population | Children & adolescents aged 3‑17 years with myopia |
What Is NVK002?
- Mechanism – Low‑concentration atropine‑sulphate formulated to inhibit myopia progression.
- Innovation – Proprietary, preservative‑free formulation that overcomes the instability of conventional low‑dose atropine.
- Shelf Life – Expected > 24 months under normal storage conditions.
- Global Positioning – Among the most advanced atropine candidates worldwide, targeting the broadest age range (3‑17 years).
Strategic Significance
- Market Expansion – Entry into Indonesia, the world’s fourth‑largest eye‑health market, aligns with Zhaoke’s global growth strategy.
- Competitive Edge – Exclusive rights to a first‑in‑class, preservative‑free myopia solution with proven intellectual‑property protection.
- Revenue Upside – Milestone payments linked to sales milestones and regulatory milestones provide upside potential for Zhaoke’s valuation.
About Zhaoke Ophthalmology
Zhaoke Ophthalmology Limited is a Hong Kong‑listed biopharmaceutical company dedicated to discovering and commercialising innovative ocular therapeutics. Its pipeline spans refractive eye diseases, retinal disorders, and ocular surface diseases, supported by a strong regulatory and commercial platform.
Forward‑Looking Statements
This release contains forward‑looking statements regarding the distribution agreement, future sales, and regulatory approvals. These statements are based on current expectations and are subject to risks and uncertainties.-Fineline Info & Tech